[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599324":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":33,"locations":41,"responsibleParty":62,"collaborators":11,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":11,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":11,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Obese subjects with HFpEF (heart failure with preserved ejection fraction)","EXPERIMENTAL",null,[13],"Drug: 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)",{"label":15,"type":16,"description":11,"interventionNames":17},"Active cardiac sarcoidosis","ACTIVE_COMPARATOR",[13],{"label":19,"type":16,"description":11,"interventionNames":20},"Healthy subjects",[13],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)","68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan",[15,19,9],[28,31],{"name":29,"affiliation":5,"role":30},"Omar Abou Ezzeddine, M.D, M.S","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":5,"role":30},"Gregorio Tersalvi, M.D",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Jake Nemgar","CONTACT","507-266-8774","nemgar.jacob@mayo.edu",{"name":32,"role":36,"phone":11,"phoneExt":11,"email":40},"tersalvi.gregorio@mayo.edu",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-92.4699,44.02163,{"lat":54,"lon":53},[57,60],{"name":58,"role":36,"phone":59,"phoneExt":11,"email":11},"Amyloid Research Team","(507) 266-4426",{"name":61,"role":30,"phone":11,"phoneExt":11,"email":11},"Omar Abou Ezzeddine, MD, MS",{"type":30,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Omar Abou Ezzeddine","Principal Investigator","100599324","phase-2-a-study-of-68ga-fibroblast-activation-protein-inhibitor-fapi-positron-emission-tomography-in-heart-failure-100599324",false,"NCT07083011","A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure","A Three-Arm, Observational, Pilot Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure","HFpEF Group Inclusion:\n\n* Patients aged ≥ 30 years old with exertional dyspnea (NYHA II and III) and LVEF ≥50%\n* BMI ≥ 30\n* New diagnosis of HFpEF based on RHC at baseline (elevated PCWP at rest and\u002For during exercise)\n\nHFpEF Group Exclusion:\n\n* Primary cardiomyopathy or pericardial disease or ≥ moderate valvular disease\n* Dyspnea due to lung disease or CAD\n* Severe anemia, liver, or renal disease\n* Active cancer\n* Systemic active inflammatory or autoimmune disease (e.g. rheumatoid arthritis, SLE, etc.)\n* Recent hospitalization (\\\u003C 30 days) or coronary revascularization (\\\u003C 90 days)\n* Patients already taking SGLT2i and\u002For GLP-1A\n* Pregnant or breastfeeding\n* Inability to tolerate supine position for the PET\u002FCT or CMR scans.\n* Contraindications for safe CMR scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator)\n* Known gadolinium allergy\n* Presence of implantable cardiac pacemaker or defibrillator or mechanical valve.\n\nCardiac Sarcoid Group Inclusion:\n\n* Ambulatory patients aged ≥ 18 years old\n* New referrals to the Sarcoid Clinic with a confirmed but untreated diagnosis of definite or probable CS based on 2014 HRS consensus (see Table 2)\n* With a positive cardiac 18F-FDG PET scan within 30 days.\n\nCardiac Sarcoid Group Exclusion:\n\n* Already on immunosuppressive therapy\n* Pregnant or breastfeeding\n* Severe liver or renal disease (estimated GFR \\\u003C 30 or dialysis-dependent)\n* Recent coronary revascularization (\\\u003C 90 days)\n* Active cancer\n* Known gadolinium allergy\n* Inability to tolerate supine position for the PET\u002FCT or CMR scans.\n* Contraindications for safe CMR scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator)\n* Presence of implantable cardiac pacemaker or defibrillator or mechanical valve.\n\nHealthy Controls Group Inclusion:\n\n* Adults ≥ 30 years old\n* No major chronic disease (cardiopulmonary, inflammatory, autoimmune, cancer, renal or liver impairment, etc.)\n* No intake of relevant medication, defined as regular intake of at least one of the following: anticoagulants, antiplatelets, antihypertensive \u002F diuretics, antidiabetics, antiarrhythmic, immunosuppressants, chemotherapy, antibiotics\u002Fantivirals\u002Fantifungals\n\nHealthy Controls Group Exclusion:\n\n* BMI ≥ 30\n* Pregnant or breastfeeding\n* Known gadolinium allergy\n* Inability to tolerate supine position for the PET\u002FCT or CMR scans.\n* Contraindications for safe CMR scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator)",true,"ALL","18 Years",{"count":76,"type":77},35,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)",[83],"Heart Failure With Preserved Ejection Fraction","2026-04-22",{"date":86,"type":87},"2026-04-27","ACTUAL",{"date":89,"type":87},"2025-11-01",{"date":91,"type":77},"2027-07",{"name":5,"class":6},1]